Agrees to review Moderna flu vaccine
Digest more
After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot
The study involved 550 healthy U.S. adults ages 18 to 75 who received either the experimental combo vaccine and a placebo or two separate shots of Moderna’s commercially available mRNA flu and COVID vaccines, according to a report published in Human Vaccines and Therapeutics.
The Food and Drug Administration’s recent decision to turn away Moderna’s application for a new flu shot for older Americans is a troubling development in health officials’ piecemeal dismantling of